Discover our portfolio



HoliStick Medical, the new start-up of the BioMedTech fund created by Truffle Capital, has obtained a license for a technology jointly owned by Harvard, MIT, Boston Children’s Hospital and Brigham & Women’s Hospital.


HoliStick Medical has access to a radically innovative medical device that could transform the way heart defects are treated. A heart defect is a problem in the structure of the heart at birth. These defects include the ventricular septal defect (VSD), a defect in the wall separating the left and right ventricles of the heart, and the atrial septal defect (ASD), where blood flows between the atria (upper chambers) of the heart. A certain flow is a normal condition before birth and immediately after birth via the foramen ovale, but when this does not close naturally after birth, it is called foramen ovale (PFO). PFO is now considered an important cause of stroke, particularly among young patients, and PFO closure is recommended to prevent stroke recurrence.


HoliStick will develop and sell a specific catheter that can repair holes in the heart using flexible structures. Designed to work with sticky and flexible materials such as patches, the device incorporates mechanisms to gently and minimally invasively close a hole without sutures or rigid devices. It meets a major medical need to improve current devices.


HoliStick intends to develop and market new medical devices based on this technology in Europe, the United States and Asia.

Contact Truffle Capital

9 + 4 =

[sg_popup id=2]


5 Rue de la Baume, 75008 Paris, France Tel: +33 1 82 28 46 00



Truffle Capital

Truffle Capital

5 Rue de la Baume 75008 Paris France
Tel: +33 1 82 28 46 00

© 2018 Truffle Capital

Truffle Capital 2018

Social Networks